SUMMARY  

• The Prescribing Information should be the source document for administration procedures.
• CARVYKTI must be administered using infusion sets fitted with an in-line filter. Do NOT use a leukocyte-depleting filter.¹
• A non-leukocyte depleting filter is commonly referred to as a blood filter. All blood and cell products must be administered through a filter in order to remove cell clots and thrombi. Standard blood filters, with a pore size of 170–260 μm, trap large aggregates and clots.²
• CARVYKTI is an engineered T cell product derived from a patient’s blood and therefore has been developed to follow standard practices of administration as a blood and cell product. To ensure the engineered T cells are not filtered out during infusion, while preventing potential agglomerates and clots of material from being infused to the patient, a non-leukocyte depleting filter (blood filter) must be used. If agglomerates/thrombi enter the bloodstream, there is a potential for the formation of clots, which can lead to pulmonary embolism.²
• In the CARTITUDE-1 study, CARVYKTI was administered using an infusion set with a blood filter with a pore size of 170 μm or larger.³
• Blood filters are also available as microagglomerate filters which have a pore size range of 10–40 μm. CARVYKTI has not been evaluated for administration with microagglomerate filters and therefore they must NOT be used during infusion.²

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 20 November 2024.